More Stories

Informist, Thursday, Feb. 12, 2026

 

Please click here to read all liners published on this story

--Biocon Oct-Dec consol net profit INR 1.44 bln vs INR 251 mln yr ago 
--Analysts saw Biocon Oct-Dec consol net profit INR 1.85 bln 
--Biocon Oct-Dec consol revenue INR 41.73 bln vs INR 38.21 bln yr ago 
--Analysts saw Biocon Oct-Dec consol revenue INR 45.41 bln 
--Biocon Apr-Dec consol net profit INR 2.60 bln vs INR 6.69 bln yr ago 
--Biocon Oct-Dec net profit includes one-time cost INR 2.93 bln 
--Biocon Apr-Dec consol revenue INR 124.10 bln vs INR 108.45 bln yr ago 
--Biocon Oct-Dec new labour codes implementation cost INR 1.75 bln 
--Biocon Oct-Dec biosimilars revenue INR 24.97 bln vs INR 22.89 bln year ago 
--Biocon Oct-Dec generics sales INR 8.51 bln vs INR 6.86 bln yr ago 
--Biocon Oct-Dec research svcs sales INR 9.17 bln vs INR 9.44 bln yr ago 
--Biocon Oct-Dec net profit excluding one-time cost is INR 4.37 bln

 

By Gunjan Rajput

 

MUMBAI – Biocon Ltd. reported over fivefold growth on year in consolidated net profit for the December quarter, marking its highest net profit in three quarters. However, its revenue rose in the single digit on year, the slowest increase in four quarters.

 

The biotechnology company's consolidated net profit for the December quarter was INR 1.44 billion, up nearly 473% on year. The company's bottom line had fallen 96% on year to INR 251 million a year ago.

 

The net profit was depressed by a one-time cost of INR 2.93 billion, including INR 1.75 billion for implementation of the new labour codes. Excluding these, the net profit would have been INR 4.37 billion. In the year-ago quarter, the company had recorded a one-time gain of INR 181 million.

 

Its revenue rose 9% on year but fell almost 3% on quarter to INR 41.73 billion. Revenue from the company's biosimilars segment rose to INR 24.97 billion, up over 9% from INR 22.89 billion a year ago. Sales of generics increased to INR 8.51 billion, up 24% on year from INR 6.86 billion. The research services revenue, however, declined nearly 3% to INR 9.17 billion.

 

Biocon reported earnings before interest, tax, depreciation, and amortisation of INR 9.51 billion for the quarter, up 21% on year. Its EBITDA margin improved to 22% from 20% a year ago.

 

The company's total expenses rose over 9% on year to INR 40.65 billion. Other expenses increased over 23% on year while the cost of materials consumed rose nearly 3%. Employee benefits expense was up over 11% on year.
 

Biocon had, through a letter in January, informed the exchanges about the acquisition of equity shares of Biocon Biologics Ltd., increasing its stake in the subsidiary to about 98% of its paid-up equity share capital on a fully diluted basis. The company's board has granted in-principle approval to acquire the remaining about 2% in Biocon Biologics from employees of the Biocon group.

 

In January, the company also raised INR 41.50 billion through a qualified institutional placement, using the proceeds primarily to fund the buyout of Mylan Inc.'s shareholding in Biocon Biologics.

 

"This quarter marks the culmination of several strategic steps that have created a stronger and simpler group structure for Biocon Limited... Finally, the integration of Biocon Biologics Limited as a wholly owned subsidiary of Biocon Limited will bring to life our unified One Biocon vision," Kiran Mazumdar-Shaw, chairperson, Biocon Group, said in a press release. 

For the nine months ended Dec. 31, Biocon's consolidated net profit fell over 61% on year to INR 2.60 billion. Revenue for the period increased nearly 19% to INR 96.63 billion. The company announced its results after market hours Thursday. Its shares closed flat at INR 375.05 on the National Stock Exchange.  End

 

Edited by Rajeev Pai

 

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

 

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

 

Informist Media Tel +91 (22) 6985-4000

Send comments to feedback@informistmedia.com

 

© Informist Media Pvt. Ltd. 2026. All rights reserved.